← Back to all trials
Completed
NCT05746416
Xience Registry In Complex Lesion of Acute Coronary Syndrome Patients witH Ticagrelor (RICH)
Conditions: Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
Sex: All
Ages: 19 Years – N/A
Enrollment: 977
Sponsor: Hanyang University Seoul Hospital
Location: Korea, Republic of
Summary
The goal of this multicenter prospective clinical cohort study is to investigate the impact of early use of low-dose Ticagrelor-based dual antiplatelet agent therapy (TDAPT) (ticagrelor 120mg daily; l-TDAPT) as compared to standard-dose TDAPT (ticagrelor 180mg daily; s-TDAPT) in outcomes of percutaneous coronary intervention (PCI).The main question it aims to answer are:Given the low ischemic risk and high bleeding tendency in Asians, the low dose TDAPT may provide better net clinical benefits of ischemic and bleeding events than the standard dose TDAPT.
Eligibility Criteria
Inclusion Criteria:19 years of age or olderacute coronary syndrome (ACS) undergoing PCIPCI for complex coronary lesions using everolimus-eluting stents (Xience®, Abbot corp, Chicago, Illinois, US)prescribed with s-TDAPT for more than 3 monthsExclusion Criteria:cardiogenic shockPCI using drug-eluting stents (DES) other than the everolimus-eluting stentsthose who had conditions requiring a long-term oral anticoagulant therapythose with life expectancy <1 year
Source: ClinicalTrials.gov (NCT05746416). StuddyBuddy aggregates publicly available trial information.
